UA73281C2 - Antitumor pharmaceutical composition based on carboplatin - Google Patents
Antitumor pharmaceutical composition based on carboplatin Download PDFInfo
- Publication number
- UA73281C2 UA73281C2 UA2001021022A UA2001021022A UA73281C2 UA 73281 C2 UA73281 C2 UA 73281C2 UA 2001021022 A UA2001021022 A UA 2001021022A UA 2001021022 A UA2001021022 A UA 2001021022A UA 73281 C2 UA73281 C2 UA 73281C2
- Authority
- UA
- Ukraine
- Prior art keywords
- carboplatin
- cyclobutanedicarboxylic acid
- pharmaceutical composition
- concentration
- aqueous solution
- Prior art date
Links
- 229960004562 carboplatin Drugs 0.000 title claims abstract description 92
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 5
- 190000008236 carboplatin Chemical compound 0.000 title 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims abstract description 90
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 239000007864 aqueous solution Substances 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 238000012876 topography Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 238000003860 storage Methods 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 10
- 239000002253 acid Substances 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 6
- 238000010998 test method Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- -1 carboplatin monohydrate Chemical class 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 238000007323 disproportionation reaction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/0091—Complexes with metal-heteroatom-bonds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ19982588A CZ292170B6 (cs) | 1998-08-14 | 1998-08-14 | Farmaceutická kompozice s protinádorovým účinkem na bázi carboplatiny |
| PCT/CZ1999/000028 WO2000009097A2 (en) | 1998-08-14 | 1999-08-10 | Pharmaceutical composition with antitumor activity on the basis of carboplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73281C2 true UA73281C2 (en) | 2005-07-15 |
Family
ID=5465233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001021022A UA73281C2 (en) | 1998-08-14 | 1999-10-08 | Antitumor pharmaceutical composition based on carboplatin |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6589988B1 (de) |
| EP (1) | EP1107750B1 (de) |
| AT (1) | ATE281832T1 (de) |
| AU (1) | AU5024599A (de) |
| BG (1) | BG105207A (de) |
| CZ (1) | CZ292170B6 (de) |
| DE (1) | DE69921832T2 (de) |
| ES (1) | ES2229737T3 (de) |
| HR (1) | HRP20010110B1 (de) |
| HU (1) | HUP0104304A3 (de) |
| NO (1) | NO20010507L (de) |
| PL (1) | PL346363A1 (de) |
| PT (1) | PT1107750E (de) |
| RU (1) | RU2188640C1 (de) |
| SK (1) | SK284711B6 (de) |
| UA (1) | UA73281C2 (de) |
| WO (1) | WO2000009097A2 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100598474B1 (ko) | 1998-04-03 | 2006-07-11 | 아지노모토 가부시키가이샤 | 항종양제 |
| AU2005329764B2 (en) * | 2005-03-28 | 2010-08-12 | Dabur Pharma Ltd. | Stable pharmaceutical compositions of platinum (II) antitumour agents |
| KR101127159B1 (ko) * | 2009-11-02 | 2012-03-20 | 한국생명공학연구원 | 식물병원성 그람음성 세균의 분비체계를 저해하는 카보프라틴 화합물을 유효성분으로 함유하는 식물병 방제제 |
| WO2020044311A1 (en) * | 2018-08-31 | 2020-03-05 | Sun Pharmaceutical Industries Limited | Parenteral dosage form of carboplatin |
| US12427104B1 (en) | 2025-04-01 | 2025-09-30 | Ingenus Pharmaceuticals, Llc | Injectable carboplatin formulations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CS269719B1 (en) * | 1986-12-29 | 1990-05-14 | Kiss Frantisek | Platinum cytostatic |
| JPH01146826A (ja) * | 1987-12-03 | 1989-06-08 | Nippon Kayaku Co Ltd | 白金化合物の凍結乾燥製剤 |
| NL8901433A (nl) * | 1989-06-06 | 1991-01-02 | Pharmachemie Bv | Carboplatinpreparaat. |
| US5455270A (en) * | 1993-08-11 | 1995-10-03 | Bristol-Myers Squibb Co. | Stabilized solutions of platinum(II) antitumor agents |
| AU5878294A (en) * | 1994-02-07 | 1995-08-21 | Kiss Laboratories S.R.O. | Anti-tumour medical preparation on the basis of carboplatin and the method of its production |
-
1998
- 1998-08-14 CZ CZ19982588A patent/CZ292170B6/cs not_active IP Right Cessation
-
1999
- 1999-08-10 PL PL99346363A patent/PL346363A1/xx not_active IP Right Cessation
- 1999-08-10 DE DE69921832T patent/DE69921832T2/de not_active Expired - Lifetime
- 1999-08-10 RU RU2001104352/14A patent/RU2188640C1/ru not_active IP Right Cessation
- 1999-08-10 WO PCT/CZ1999/000028 patent/WO2000009097A2/en not_active Ceased
- 1999-08-10 ES ES99934452T patent/ES2229737T3/es not_active Expired - Lifetime
- 1999-08-10 SK SK209-2001A patent/SK284711B6/sk not_active IP Right Cessation
- 1999-08-10 AU AU50245/99A patent/AU5024599A/en not_active Abandoned
- 1999-08-10 HU HU0104304A patent/HUP0104304A3/hu unknown
- 1999-08-10 PT PT99934452T patent/PT1107750E/pt unknown
- 1999-08-10 HR HR20010110A patent/HRP20010110B1/xx not_active IP Right Cessation
- 1999-08-10 US US09/762,458 patent/US6589988B1/en not_active Expired - Fee Related
- 1999-08-10 AT AT99934452T patent/ATE281832T1/de not_active IP Right Cessation
- 1999-08-10 EP EP99934452A patent/EP1107750B1/de not_active Expired - Lifetime
- 1999-10-08 UA UA2001021022A patent/UA73281C2/uk unknown
-
2001
- 2001-01-30 NO NO20010507A patent/NO20010507L/no not_active Application Discontinuation
- 2001-01-31 BG BG105207A patent/BG105207A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2188640C1 (ru) | 2002-09-10 |
| BG105207A (en) | 2001-07-31 |
| ATE281832T1 (de) | 2004-11-15 |
| ES2229737T3 (es) | 2005-04-16 |
| NO20010507D0 (no) | 2001-01-30 |
| WO2000009097A2 (en) | 2000-02-24 |
| DE69921832D1 (de) | 2004-12-16 |
| US6589988B1 (en) | 2003-07-08 |
| HUP0104304A3 (en) | 2004-04-28 |
| AU5024599A (en) | 2000-03-06 |
| EP1107750A2 (de) | 2001-06-20 |
| NO20010507L (no) | 2001-01-30 |
| PL346363A1 (en) | 2002-02-11 |
| EP1107750B1 (de) | 2004-11-10 |
| HUP0104304A2 (hu) | 2002-03-28 |
| PT1107750E (pt) | 2005-02-28 |
| HRP20010110A2 (en) | 2002-02-28 |
| SK284711B6 (sk) | 2005-09-08 |
| WO2000009097A3 (en) | 2000-05-18 |
| CZ292170B6 (cs) | 2003-08-13 |
| DE69921832T2 (de) | 2005-11-03 |
| CZ258898A3 (cs) | 2000-02-16 |
| HRP20010110B1 (en) | 2005-10-31 |
| SK2092001A3 (en) | 2001-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2099350C1 (ru) | Ассоциаты депротонированной гиалуроновой кислоты, способ их получения, фармацевтическая композиция, содержащая ассоциаты депротонированной гиалуроновой кислоты, и способ ее получения | |
| AP957A (en) | Novel stable liquid paracetamol compositions, and method for preparing same. | |
| EP1225898B1 (de) | Pharmazeutische zusammensetzungen ein fluorchinolonantibiotikum und xanthangummi enthaltend | |
| KR101602000B1 (ko) | 안정한 트라넥삼산과 아스코르브산 함유 의약 조성물 | |
| EP3189841A1 (de) | Pharmazeutische zubereitung mit cephalosporin mit katecholgruppen | |
| Doverspike et al. | Nitric oxide releasing two-part creams containing S-nitrosoglutathione and zinc oxide for potential topical antimicrobial applications | |
| KR20110116194A (ko) | 헤스페리딘 함유 조성물 | |
| JPWO2008023807A1 (ja) | 安定化された医薬組成物 | |
| JPWO2001080858A1 (ja) | 安定化液状製剤 | |
| CN110711193A (zh) | 一种复方阿莫西林可溶性粉及其制备方法 | |
| KR100440354B1 (ko) | 티아가빈염산염함유약학적조성물및그제조방법 | |
| JP4929352B2 (ja) | 注入可能なパラセタモール液剤 | |
| RU2188640C1 (ru) | Фармацевтическая композиция с противоопухолевой активностью на основе карбоплатина | |
| HU177557B (en) | Process for preparing stable aequous sterile solution of cys-platinic/ii/-diamine-dichloride | |
| JPS5914447B2 (ja) | ｐＨおよび色安定化非経口投与用水性抗性物質組成物 | |
| EP0159777A1 (de) | Stabilisiertes 4-Carbamoyl-imidazolium-5-olat | |
| SU1706372A3 (ru) | Способ получени водных растворов винкристина или винбластина | |
| KR0164601B1 (ko) | 비스-인돌알칼로이드를 함유하는 주사 용액및 그 제조방법 | |
| JPS6360008B2 (de) | ||
| RU2611839C1 (ru) | Состав для производства йодосодержащих биологически активных добавок | |
| CN101621992A (zh) | 具有醇糖-基的缓冲液的奥沙利铂药物组合物 | |
| HU181940B (en) | Process for producing solutions of vincane derivatives for parentheral application | |
| AU2009349348B2 (en) | Liquid pharmaceutical form of alkylphosphocholine and method of preparing same | |
| US4554164A (en) | Parenteral formulation | |
| KR960004018B1 (ko) | L-글루타민과 수용성아줄렌 복합 항궤양용 제제의 안정화 방법 |